Publikationen, an denen er mitarbeitet Beatriz Arrizabalaga Amuchastegui (9)

2020

  1. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

  2. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

2017

  1. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

2015

  1. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

    Annals of Hematology, Vol. 94, Núm. 5, pp. 779-787

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  2. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309